本文關(guān)鍵詞：粒細(xì)胞集落刺激因子治療乙型肝炎相關(guān)慢加急性肝衰竭隨機(jī)對照臨床研究　出處：《傳染病信息》2016年05期 　論文類型：期刊論文

  更多相關(guān)文章： 粒細(xì)胞集落刺激因子 HBV 慢加急性肝衰竭 臨床研究

【摘要】：目的評價重組人粒細(xì)胞集落刺激因子(recombinant granulocyte-colony stimulating factor,r G-CSF)治療乙型肝炎相關(guān)慢加急性肝衰竭(hepatitis B virus-associated acute-on-chronic liver failure,HBV-ACLF)的有效性和安全性。方法將99例ACLF患者隨機(jī)分為2組,試驗組49例,對照組50例。對照組給予內(nèi)科綜合治療,試驗組在綜合治療基礎(chǔ)上接受r G-CSF300μg,1次/d,皮下注射,共計6針,然后減量至隔日1次,共6次,總計12針。結(jié)果生存分析表明,試驗組治療1月、3月的生存率分別為91.3%和72.9%,大于對照組的63.7%和50.0%(P0.05)。治療期間無嚴(yán)重不良反應(yīng)發(fā)生。結(jié)論r G-CSF能夠顯著提高HBV-ACLF患者的生存率,并且有較高的安全性。
[Abstract]:Objective to evaluate the recombinant granulocyte-colony stimulating factor of recombinant human granulocyte colony stimulating factor. R G-CSF in the treatment of chronic hepatitis B associated with acute liver failure. Hepatitis B virus-associated acute-on-chronic liver failure. Methods 99 patients with ACLF were randomly divided into two groups: experimental group (49 cases) and control group (50 cases). The trial group received rG-CSF 300 渭 g / d, subcutaneously for 6 doses, and then reduced to 6 times every other day for a total of 12 doses. Results Survival analysis showed that there were 12 doses of rG-CSF 300 渭 g / d in the trial group. The survival rates of the trial group on January and March were 91.3% and 72.9%, respectively. There was no serious adverse reaction during the treatment. Conclusion rG-CSF can significantly improve the survival rate of HBV-ACLF patients. And has high safety.
【作者單位】： 北京大學(xué)解放軍第三0二醫(yī)院教學(xué)醫(yī)院肝衰竭診療研究中心;
【基金】：北京市科技計劃首都臨床特色應(yīng)用研究項目(Z131107002213157)
【分類號】：R512.62;R575.3
【正文快照】： 近年來,粒細(xì)胞集落刺激因子治療肝衰竭成為臨床研究熱點,特別是酒精性肝衰竭和乙型肝炎相關(guān)慢加急性肝衰竭(hepatitis B virus-associated acute-on-chronic liver failure,HBV-ACLF)的隨機(jī)對照臨床研究顯示其具有治療作用,且安全性良好[1-2]。2014年亞太肝病協(xié)會頒布的《慢加

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 曹慧;張e，

本文編號：1438413